Recipharm and Hadasit partner to deliver seamless chemical and clinical services
Recipharm, the contract development and manufacturing organisation (CDMO), has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological and chemical services.
Located in Israel, Hadasit, a wholly owned subsidiary of Hadassah Medical Organisation (HMO), offers a variety of research, development and consulting services to customers, primarily in the Middle East.
With its unique access to HMO's expert clinicians and researchers, the company provides clinical-oriented R&D services that can assist customers from the point of early preclinical development up to regulatory approval, saving valuable time and money.
Recipharm’s facility in Israel has partnered with the firm as part of its growth plans in the market and to enable a more seamless customer experience as pharmaceutical products progress through clinical phases.
Commenting on the partnership, Dr. Sylvia Kachalsky, Site Manager at Recipharm in Israel, said: “Developing a drug involves chemical, biological and clinical expertise. Our partnership with Hadasit means we can offer these services more efficiently and manage projects seamlessly from development to clinic.”
Recipharm established in Israel in 2015 and since then the business has grown to serve more than 50 customers, primarily in Israel and the USA.
Dr. Kachalsky continued: “The partnership will support business growth in Israel, giving Recipharm access to the majority of the clinical trials taking place in the country. While the field of chemistry services is relatively new to this market, the growth potential is substantial, with more than 800 biotech companies in Israel and the number and size of these companies continuing to grow.”
“By collaborating with one of the most prestigious hospitals in the region and its commercial arm, we believe this will support our goal to become the most trusted CDMO in the region.”
Hadasit brings a number of specialist services to the partnership, including in vitro analysis in various models, access to and analysis of human samples, in vivo models for multiple medical conditions, input regarding medical indications and the conducting of clinical trials at all phases.
Dr. Tamar Raz, CEO at Hadasit said: “Through the partnership we will be able to offer a full service for the synthesis and testing of compounds. Working with Recipharm, our team will gain professional input regarding the compounds that Hadassah researchers and Hadasit companies are developing, including synthesis and medicinal chemistry challenges. We are looking forward to a mutually beneficial long-term partnership which will ultimately help both companies to grow and support the pharmaceutical industry in Israel.”
Recipharm and Hadasit will be exhibiting at the 17th MIXiii-BIOMED 2018 Conference and Exhibition in Tel Aviv, Israel, May 15 -17, 2018. Visit the Recipharm team at stand 86 and the Hadasit team at stand 2.
Sylvia Kachalsky, Site Manager, email: email@example.com, phone: +972 544 785 711, or firstname.lastname@example.org, +972 2 677 8757
For media enquiries, please contact Lindsay Baldry at ramarketing: email@example.com, +44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com.
Hadasit is the technology transfer company of Hadassah Medical Center in Jerusalem. Hadasit transforms the cutting-edge research coming out of Hadassah into marketable medical technologies. Hadasit turns ground-breaking ideas into viable products and services that can change the world and better humanity. For more than a century, Hadassah has set the standard of excellence for medical care and research. Hadassah doctors and scientists are on the frontlines, uniquely positioned to pinpoint ever-evolving medical needs. Their experience and ingenuity has yielded new ideas with huge potential in all areas of medicine, including therapeutics, diagnostic medical devices, and digital health. More than half of all hospital research in Israel is conducted at Hadassah. Hadasit is Hadassah’s vehicle for commercialization of the intellectual property and R&D capabilities developed there. Hadasit holds exclusive rights to every innovation and invention emerging from Hadassah and we are dedicated to bringing these life-saving technologies to the general public. Hadasit identifies, protects, nurtures and commercializes the discoveries made at Hadassah Medical Center. Hadasit also handles the contractual aspects of all services offered to the industry, as well as pre-clinical studies conducted at Hadassah. Hadasit spins off companies, licenses technologies, and collaborates with leading international companies and research facilities. Hadasit's portfolio includes more than 250 families of active patents which have yielded numerous medical and commercial breakthroughs.
For more information on Hadasit please visit www.hadasit.org
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00